Alphamab Oncology (HK:9966)
:9966
Want to see HK:9966 full AI Analyst Report?
9966 Stock Chart & Stats
HK$11.90
-HK$0.05(-1.46%)
At close: 4:00 PM EST
HK$11.90
-HK$0.05(-1.46%)
Day’s Range― - ―
52-Week RangeHK$6.01 - HK$15.75
Previous CloseN/A
Volume1.49M
Average Volume (3M)3.94M
Market Cap
HK$6.97B
Enterprise ValueHK$7.48B
Total Cash (Recent Filing)HK$1.35B
Total Debt (Recent Filing)HK$123.03M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding974,381,700
10 Day Avg. Volume3,868,184
30 Day Avg. Volume3,937,702
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)4.94
Price to Sales (P/S)15.34
P/FCF Ratio-55.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.60Price Target Upside-19.33% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.15
Revenue Forecast (FY)HK$392.45M
Bulls Say, Bears Say
Bulls Say
High Gross MarginSustaining ~77% gross margins is structurally favorable for a biologics firm: it supports long‑term operating leverage as commercial volumes grow, cushions SG&A and R&D spending, and preserves unit economics for pricing and partnership negotiations despite top‑line swings.
Conservative Balance SheetVery low financial leverage and a sizeable equity base give the company durable funding flexibility typical for biotech. Low debt reduces refinancing risk and preserves optionality to fund clinical programs, M&A, or partnerships without immediate covenant pressure.
Focused Antibody Oncology PlatformA clear focus on antibody-based oncology and capabilities spanning discovery through commercialization create structural advantages: specialized R&D expertise, IP depth, and the ability to capture downstream commercial value rather than only licensing early assets.
Bears Say
Sharp Revenue Decline And LossesA ~30% top-line drop coupled with a ~111M net loss signals weakening commercial execution or product demand. Persistent revenue deterioration undermines margin leverage and increases the probability of further program cuts or financing actions within a 2–6 month horizon.
Renewed Cash BurnReturn to significant negative operating and free cash flow materially raises funding risk for a clinical-stage biotech. Sustained cash burn can force dilutive equity raises or restrictive partner deals, constraining R&D and commercialization plans over the medium term.
Inconsistent Profitability And Performance VolatilitySwinging between profit and loss reflects unstable execution or product mix, making earnings and cash‑flow forecasting unreliable. This inconsistency complicates capital allocation, investor confidence, and long‑range planning for manufacturing and regulatory investment.
Alphamab Oncology News
9966 FAQ
What was Alphamab Oncology’s price range in the past 12 months?
Alphamab Oncology lowest stock price was HK$6.01 and its highest was HK$15.75 in the past 12 months.
What is Alphamab Oncology’s market cap?
Alphamab Oncology’s market cap is HK$6.97B.
When is Alphamab Oncology’s upcoming earnings report date?
Alphamab Oncology’s upcoming earnings report date is Aug 20, 2026 which is in 75 days.
How were Alphamab Oncology’s earnings last quarter?
Alphamab Oncology released its earnings results on Mar 25, 2026. The company reported -HK$0.154 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.154.
Is Alphamab Oncology overvalued?
According to Wall Street analysts Alphamab Oncology’s price is currently Overvalued.
Does Alphamab Oncology pay dividends?
Alphamab Oncology does not currently pay dividends.
What is Alphamab Oncology’s EPS estimate?
Alphamab Oncology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alphamab Oncology have?
Alphamab Oncology has 974,381,700 shares outstanding.
What happened to Alphamab Oncology’s price movement after its last earnings report?
Alphamab Oncology reported an EPS of -HK$0.154 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.98%.
Which hedge fund is a major shareholder of Alphamab Oncology?
Currently, no hedge funds are holding shares in HK:9966
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alphamab Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$9.60 (-19.33% Downside)
HK$9.60 (-19.33% Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
239.25%
12-Months-Change
Fundamentals
Return on Equity
-6.26%
Trailing 12-Months
Asset Growth
-2.09%
Trailing 12-Months
Company Description
Alphamab Oncology
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
9966 Stock 12 Month Forecast
Average Price Target
HK$9.60
▼(-19.33% Downside)
Technical Analysis
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---